These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
365 related articles for article (PubMed ID: 9120000)
1. Modulation of fibroblast growth factor-2 receptor binding, dimerization, signaling, and angiogenic activity by a synthetic heparin-mimicking polyanionic compound. Miao HQ; Ornitz DM; Aingorn E; Ben-Sasson SA; Vlodavsky I J Clin Invest; 1997 Apr; 99(7):1565-75. PubMed ID: 9120000 [TBL] [Abstract][Full Text] [Related]
2. Modulation of fibroblast growth factor-2 receptor binding, signaling, and mitogenic activity by heparin-mimicking polysulfonated compounds. Liekens S; Leali D; Neyts J; Esnouf R; Rusnati M; Dell'Era P; Maudgal PC; De Clercq E; Presta M Mol Pharmacol; 1999 Jul; 56(1):204-13. PubMed ID: 10385702 [TBL] [Abstract][Full Text] [Related]
3. Two hierarchies of FGF-2 signaling in heparin: mitogenic stimulation and high-affinity binding/receptor transphosphorylation. Krufka A; Guimond S; Rapraeger AC Biochemistry; 1996 Aug; 35(34):11131-41. PubMed ID: 8780517 [TBL] [Abstract][Full Text] [Related]
4. Antiproliferative activity to glomerular mesangial cells and receptor binding of a heparin-mimicking polyaromatic anionic compound. Katz A; Vlodavsky I; Davies M; Miao HQ; Ben-Sasson SA; Darmon D; Hurwitz H; Borgel H; Benezra M J Am Soc Nephrol; 1997 Nov; 8(11):1688-97. PubMed ID: 9355071 [TBL] [Abstract][Full Text] [Related]
5. Fibroblast growth factor-2 can mediate cell attachment by linking receptors and heparan sulfate proteoglycans on neighboring cells. Richard C; Liuzzo JP; Moscatelli D J Biol Chem; 1995 Oct; 270(41):24188-96. PubMed ID: 7592623 [TBL] [Abstract][Full Text] [Related]
6. Endogenous basic fibroblast growth factor displaced by heparin from the lumenal surface of human blood vessels is preferentially sequestered by injured regions of the vessel wall. Medalion B; Merin G; Aingorn H; Miao HQ; Nagler A; Elami A; Ishai-Michaeli R; Vlodavsky I Circulation; 1997 Apr; 95(7):1853-62. PubMed ID: 9107173 [TBL] [Abstract][Full Text] [Related]
7. Differentiation of coronary smooth muscle cells to a cell cycle-arrested hypertrophic growth status by a synthetic non-toxic heparin-mimicking compound. Schmidt A; Vlodavsky I; Völker W; Buddecke E Atherosclerosis; 1999 Dec; 147(2):387-97. PubMed ID: 10559525 [TBL] [Abstract][Full Text] [Related]
8. Differential tyrosine phosphorylation of fibroblast growth factor (FGF) receptor-1 and receptor proximal signal transduction in response to FGF-2 and heparin. Lundin L; Rönnstrand L; Cross M; Hellberg C; Lindahl U; Claesson-Welsh L Exp Cell Res; 2003 Jul; 287(1):190-8. PubMed ID: 12799194 [TBL] [Abstract][Full Text] [Related]
9. Antiproliferative activity to vascular smooth muscle cells and receptor binding of heparin-mimicking polyaromatic anionic compounds. Benezra M; Ben-Sasson SA; Regan J; Chang M; Bar-Shavit R; Vlodavsky I Arterioscler Thromb; 1994 Dec; 14(12):1992-9. PubMed ID: 7981190 [TBL] [Abstract][Full Text] [Related]
10. Kinetic model for FGF, FGFR, and proteoglycan signal transduction complex assembly. Ibrahimi OA; Zhang F; Hrstka SC; Mohammadi M; Linhardt RJ Biochemistry; 2004 Apr; 43(16):4724-30. PubMed ID: 15096041 [TBL] [Abstract][Full Text] [Related]
11. A short peptide domain of platelet factor 4 blocks angiogenic key events induced by FGF-2. Hagedorn M; Zilberberg L; Lozano RM; Cuevas P; Canron X; Redondo-Horcajo M; Gimenez-Gallego G; Bikfalvi A FASEB J; 2001 Mar; 15(3):550-2. PubMed ID: 11259363 [TBL] [Abstract][Full Text] [Related]
12. Fibroblast growth factor receptor-1 mediates the inhibition of endothelial cell proliferation and the promotion of skeletal myoblast differentiation by SPARC: a role for protein kinase A. Motamed K; Blake DJ; Angello JC; Allen BL; Rapraeger AC; Hauschka SD; Sage EH J Cell Biochem; 2003 Oct; 90(2):408-23. PubMed ID: 14505356 [TBL] [Abstract][Full Text] [Related]